Story

Braveheart Bio Prices IPO at $18 Per Share, Raising $382.5 Million

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20261 min read
Braveheart Bio Prices IPO at $18 Per Share, Raising $382.5 Million
Text size
Background

Braveheart Bio, Inc., a clinical-stage biopharmaceutical company, announced it has priced its initial public offering at $18.00 per share. The offering is expected to raise gross proceeds of $382.5 million to advance its pipeline of cardiovascular disease treatments.

Offering Details

According to a company press release, Braveheart Bio is offering 21,250,000 shares of its common stock. The stated gross proceeds do not account for underwriting discounts, commissions, and other related expenses.

Underwriters have also been granted a 30-day option to purchase up to an additional 3,187,500 shares at the IPO price. The company's shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026, under the ticker symbol "BRVE". The offering is anticipated to close on August 7, 2026, subject to customary closing conditions.

Use of Proceeds and Pipeline

Sample IUX Markets – In-articleAd

The capital raised is expected to support the development of the San Francisco-based company's lead product candidate, BHB-1893. Braveheart Bio is focused on developing treatments for cardiovascular diseases.

BHB-1893 is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, a condition where the heart muscle becomes abnormally thick.

Underwriting Syndicate

A consortium of investment banks is managing the deal. Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor are serving as joint book-running managers for the offering.

Read next

More on Stocks
Back to latest news

LATEST